vs

Side-by-side financial comparison of GLOBUS MARITIME LTD (GLBS) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $9.5M, roughly 1.3× GLOBUS MARITIME LTD). GLOBUS MARITIME LTD runs the higher net margin — -19.6% vs -1398.3%, a 1378.7% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 0.2%).

Globus Maritime Ltd is a global shipping enterprise specializing in ownership, operation and chartering of dry bulk cargo vessels. It transports iron ore, coal, grain and other industrial raw materials across major global trade routes, serving clients in logistics, commodities trading and manufacturing sectors worldwide.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

GLBS vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.3× larger
RNA
$12.5M
$9.5M
GLBS
Growing faster (revenue YoY)
RNA
RNA
+433.8% gap
RNA
434.0%
0.2%
GLBS
Higher net margin
GLBS
GLBS
1378.7% more per $
GLBS
-19.6%
-1398.3%
RNA

Income Statement — Q2 FY2025 vs Q3 FY2025

Metric
GLBS
GLBS
RNA
RNA
Revenue
$9.5M
$12.5M
Net Profit
$-1.9M
$-174.4M
Gross Margin
Operating Margin
-4.3%
-1513.5%
Net Margin
-19.6%
-1398.3%
Revenue YoY
0.2%
434.0%
Net Profit YoY
-157.0%
-117.0%
EPS (diluted)
$-0.09
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GLBS
GLBS
RNA
RNA
Q3 25
$12.5M
Q2 25
$9.5M
$3.8M
Q1 25
$1.6M
Q4 24
$3.0M
Q3 24
$2.3M
Q2 24
$9.5M
$2.0M
Q1 24
$3.5M
Q4 23
$2.2M
Net Profit
GLBS
GLBS
RNA
RNA
Q3 25
$-174.4M
Q2 25
$-1.9M
$-157.3M
Q1 25
$-115.8M
Q4 24
$-102.3M
Q3 24
$-80.4M
Q2 24
$3.3M
$-70.8M
Q1 24
$-68.9M
Q4 23
$-60.4M
Operating Margin
GLBS
GLBS
RNA
RNA
Q3 25
-1513.5%
Q2 25
-4.3%
-4448.7%
Q1 25
-8360.9%
Q4 24
-4069.6%
Q3 24
-4200.9%
Q2 24
39.2%
-4040.4%
Q1 24
-2178.6%
Q4 23
-3043.5%
Net Margin
GLBS
GLBS
RNA
RNA
Q3 25
-1398.3%
Q2 25
-19.6%
-4089.3%
Q1 25
-7360.0%
Q4 24
-3439.5%
Q3 24
-3441.7%
Q2 24
34.5%
-3461.8%
Q1 24
-1943.4%
Q4 23
-2756.2%
EPS (diluted)
GLBS
GLBS
RNA
RNA
Q3 25
$-1.27
Q2 25
$-0.09
$-1.21
Q1 25
$-0.90
Q4 24
$-0.80
Q3 24
$-0.65
Q2 24
$0.16
$-0.65
Q1 24
$-0.79
Q4 23
$-0.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GLBS
GLBS
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$48.3M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$173.1M
$1.9B
Total Assets
$309.4M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GLBS
GLBS
RNA
RNA
Q3 25
$350.2M
Q2 25
$48.3M
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$70.8M
$575.8M
Q1 24
$471.4M
Q4 23
$185.1M
Stockholders' Equity
GLBS
GLBS
RNA
RNA
Q3 25
$1.9B
Q2 25
$173.1M
$1.2B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$1.5B
Q2 24
$178.9M
$1.2B
Q1 24
$830.9M
Q4 23
$500.8M
Total Assets
GLBS
GLBS
RNA
RNA
Q3 25
$2.1B
Q2 25
$309.4M
$1.4B
Q1 25
$1.5B
Q4 24
$1.6B
Q3 24
$1.6B
Q2 24
$256.3M
$1.3B
Q1 24
$951.5M
Q4 23
$628.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GLBS
GLBS
RNA
RNA
Operating Cash FlowLast quarter
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GLBS
GLBS
RNA
RNA
Q3 25
$-156.2M
Q2 25
$-199.7M
Q1 25
$-124.8M
Q4 24
$-99.9M
Q3 24
$-65.6M
Q2 24
$-65.0M
Q1 24
$-70.4M
Q4 23
$16.5M
Free Cash Flow
GLBS
GLBS
RNA
RNA
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
Q4 23
$15.6M
FCF Margin
GLBS
GLBS
RNA
RNA
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Q4 23
713.1%
Capex Intensity
GLBS
GLBS
RNA
RNA
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Q4 23
39.4%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GLBS
GLBS

Other$4.8M51%
Property Plant And Equipment Subject To Operating Leases$4.7M49%

RNA
RNA

Segment breakdown not available.

Related Comparisons